Antiseptic polymethylmethacrylate bone cement
AssigneeHeraeus Medical GmbH
InventorsSebastian VOGT, Lorena CALDERÓN ORTIZ
Life of this patent
Estimating the term…
Abstract
An antiseptic composition for use as bone cement, in particular an antiseptic polymethylmethacrylate bone cement. The composition can be cured and comprises a pharmacologically tolerable salt of a monoperoxy dicarboxylic acid, whereby the salt of the monoperoxy dicarboxylic acid can be dissolved from the composition in the presence of water. Preferably, the salt of the monoperoxy dicarboxylic acid in the composition is used in the form of a powder, whereby the powder has a mean particle size of not more than 250 μm. Preferably, the salt of the monoperoxy dicarboxylic acid, in solution at room temperature, is not degraded within 5 min by the catalase enzyme.
Claims24
Composition for use as a bone cement, whereby the composition can be cured, wherein the composition comprises a pharmacologically tolerable salt of a monoperoxy dicarboxylic acid and the salt of the monoperoxy dicarboxylic acid can be dissolved from the composition in the presence of water.
Kit 1, comprising a paste A and a paste B, whereby
- (a) paste A contains:
- (a1) at least one monomer for radical polymerisation;
- (a2) at least one organic polymer that is soluble in (a1);
- (a3) optionally, at least one polymerisation inhibitor;
- and
- (a4) at least one component of a redox initiator system;
- (b) paste B contains:
- (b1) at least one monomer for radical polymerisation;
- (b2) at least one organic polymer that is soluble in (b1), and
- (b3) at least one polymerisation accelerator;
- and whereby at least one of the pastes A or B contains, as component (a5) or (b4), a pharmacologically tolerable salt of a monoperoxy dicarboxylic acid.
Kit comprising a powder component C and a liquid monomer component D, whereby
- (c) powder component C contains:
- (c1) at least one powdered poly(meth)acrylate;
- (c2) at least one powdered radiopaquer;
- (c3) at least one polymerisation initiator;
- (d) monomer component D contains:
- (d1) at least one monomer for radical polymerisation;
- (d2) optionally, at least one polymerisation inhibitor;
- (d3) optionally, at least one organic polymer that is soluble in (d1), and
- (d4) at least one polymerisation accelerator;
- and whereby powder component C contains, as component (c4), a pharmacologically tolerable salt of a monoperoxy dicarboxylic acid.
Dependencies are inferred from the claim text.